219 related articles for article (PubMed ID: 8294859)
21. Superantigen-reactive CD4+ T cells are required to stimulate B cells after infection with mouse mammary tumor virus.
Held W; Shakhov AN; Izui S; Waanders GA; Scarpellino L; MacDonald HR; Acha-Orbea H
J Exp Med; 1993 Feb; 177(2):359-66. PubMed ID: 8093892
[TBL] [Abstract][Full Text] [Related]
22. Expression of a MHC class II transgene determines both superantigenicity and susceptibility to mammary tumor virus infection.
Pucillo C; Cepeda R; Hodes RJ
J Exp Med; 1993 Oct; 178(4):1441-5. PubMed ID: 8397273
[TBL] [Abstract][Full Text] [Related]
23. Association of a V beta 2-specific superantigen with a tumorigenic milk-borne mouse mammary tumor virus.
Hodes RJ; Novick MB; Palmer LD; Knepper JE
J Immunol; 1993 Feb; 150(4):1422-8. PubMed ID: 8094408
[TBL] [Abstract][Full Text] [Related]
24. Early neutralizing antibody response against mouse mammary tumor virus: critical role of viral infection and superantigen-reactive T cells.
Luther SA; Maillard I; Luthi F; Scarpellino L; Diggelmann H; Acha-Orbea H
J Immunol; 1997 Sep; 159(6):2807-14. PubMed ID: 9300703
[TBL] [Abstract][Full Text] [Related]
25. Maternal transfer of infectious mouse mammary tumor retroviruses does not depend on clonal deletion of superantigen-reactive V beta 14+ T cells.
Penninger JM; Wallace VA; Timms E; Mak TW
Eur J Immunol; 1994 May; 24(5):1102-8. PubMed ID: 8181521
[TBL] [Abstract][Full Text] [Related]
26. Activation of natural killer cells by mouse mammary tumor virus C4 in BALB/c and T-cell receptor V beta 2-transgenic mice.
Gill R; Wang H; Bluethmann H; Iglesias A; Wei WZ
Cancer Res; 1994 Mar; 54(6):1529-35. PubMed ID: 8137259
[TBL] [Abstract][Full Text] [Related]
27. Transfer of endogenous retroviral superantigen from donor to recipient B cells following priming to induce peripheral T cell tolerance.
Modlin CS; Todd GT; Cohen TD; Fairchild RL
Cell Immunol; 1995 Sep; 164(2):217-26. PubMed ID: 7656330
[TBL] [Abstract][Full Text] [Related]
28. The role of superantigens in the immunobiology of retroviruses.
Huber BT; Beutner U; Subramanyam M
Ciba Found Symp; 1994; 187():132-40; discussion 140-3. PubMed ID: 7796668
[TBL] [Abstract][Full Text] [Related]
29. Antibodies to the C-terminal dipeptide of mouse mammary tumor virus [MMTV(SW)] superantigen effectively inhibit T-cell activation in vivo.
Astori M; Karapetian O
J Gen Virol; 1998 Jan; 79 ( Pt 1)():57-60. PubMed ID: 9460923
[TBL] [Abstract][Full Text] [Related]
30. A highly sensitive in vitro infection assay to explore early stages of mouse mammary tumor virus infection.
Vacheron S; Renno T; Acha-Orbea H
J Virol; 1997 Oct; 71(10):7289-94. PubMed ID: 9311804
[TBL] [Abstract][Full Text] [Related]
31. A mouse mammary tumor virus-like long terminal repeat superantigen in human breast cancer.
Wang Y; Jiang JD; Xu D; Li Y; Qu C; Holland JF; Pogo BG
Cancer Res; 2004 Jun; 64(12):4105-11. PubMed ID: 15205319
[TBL] [Abstract][Full Text] [Related]
32. T cell receptor V beta repertoire in mice lacking endogenous mouse mammary tumor provirus.
Braun MY; Jouvin-Marche E; Marche PN; MacDonald HR; Acha-Orbea H
Eur J Immunol; 1995 Mar; 25(3):857-62. PubMed ID: 7705418
[TBL] [Abstract][Full Text] [Related]
33. Initial stages of mammary tumor virus infection are superantigen independent.
Pobezinskaya Y; Chervonsky AV; Golovkina TV
J Immunol; 2004 May; 172(9):5582-7. PubMed ID: 15100301
[TBL] [Abstract][Full Text] [Related]
34. C3H mouse mammary tumor virus superantigen function requires a splice donor site in the envelope gene.
Mustafa F; Lozano M; Dudley JP
J Virol; 2000 Oct; 74(20):9431-40. PubMed ID: 11000212
[TBL] [Abstract][Full Text] [Related]
35. Early increases in superantigen-specific Foxp3+ regulatory T cells during mouse mammary tumor virus infection.
Cabrera G; Burzyn D; Mundiñano J; Courreges MC; Camicia G; Lorenzo D; Costa H; Ross SR; Nepomnaschy I; Piazzon I
J Virol; 2008 Aug; 82(15):7422-31. PubMed ID: 18495774
[TBL] [Abstract][Full Text] [Related]
36. Quantitation of viral antigens released into plasma and culture fluids by murine mammary tumor cells.
Ritzi EM; Smith BA; Stolfi RL; Martin DS
Cancer Res; 1981 Oct; 41(10):3885-90. PubMed ID: 6269731
[TBL] [Abstract][Full Text] [Related]
37. The use of mammary tumor virus (Mtv)-negative and single-Mtv mice to evaluate the effects of endogenous viral superantigens on the T cell repertoire.
Scherer MT; Ignatowicz L; Pullen A; Kappler J; Marrack P
J Exp Med; 1995 Nov; 182(5):1493-504. PubMed ID: 7595219
[TBL] [Abstract][Full Text] [Related]
38. A V beta 8.2-specific superantigen from exogenous mouse mammary tumor virus carried by FM mice.
Yoshimoto T; Nagase H; Nakano H; Matsuzawa A; Nariuchi H
Eur J Immunol; 1994 Jul; 24(7):1612-9. PubMed ID: 7913038
[TBL] [Abstract][Full Text] [Related]
39. A V beta 4-specific superantigen encoded by a new exogenous mouse mammary tumor virus.
Maillard I; Erny K; Acha-Orbea H; Diggelmann H
Eur J Immunol; 1996 May; 26(5):1000-6. PubMed ID: 8647159
[TBL] [Abstract][Full Text] [Related]
40. Differential reactivity of TCR Vbeta10 alleles to a mouse mammary tumor virus superantigen.
Maillard I; Xenarios I; Diggelmann H; Orbea HA
Eur J Immunol; 1998 Oct; 28(10):3075-85. PubMed ID: 9808176
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
